Oviva, a digital provider of Type 2 diabetes treatment in Europe, has raised $21 million in Series B funding.
The new capital will be used to further develop Oviva’s technology and expand in Europe to serve the millions of patients not accessing treatment today. It brings the total amount raised by Oviva to date to $34 million.
“The new financing allows us to roll out our uniquely effective solution to large patient populations rapidly across Europe and further develop the underlying technology to better address patients’ unmet needs,” said Kai Eberhardt, CEO, and co-founder of Oviva.
Oviva offers an evidence-based digital solution to stop the progression of and reverse Type 2 diabetes and obesity-related conditions.
Patients receive tailored nutrition advice and personalized coaching via their phones. Oviva’s technology-supported treatment has consistently demonstrated higher patient uptake, retention, and outcomes at lower costs compared to face-to-face therapy.
The company’s technology allows patients to self-record their food intake, weight, activity, symptoms, and educate themselves about their disease and healthy behaviors, and communicate with other patients and their care providers.
Oviva has treated 90,000 patients to-date across the UK, Germany, France, Switzerland and the UAE, consistently doubling each year for the last 3 years.
“Behaviour change is the safest and most cost-effective way of preventing and managing diet-related health conditions including Type 2 diabetes,” commented Lucy Jones, clinical director of Oviva. “Our technology, empowers patients to take a leading role in managing their health, improves compliance and outcomes.”
- Oviva. (2020, Jan. 15). Oviva Raises $21m to Roll Out Digital Diabetes Treatment in Europe. PR Newswire. Retrieved Jan 15, 2020, from https://prnmedia.prnewswire.com/news-releases/oviva-raises-21m-to-roll-out-digital-diabetes-treatment-in-europe-845262602.html